BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 08/14/23

2023-08-14 11:03:10 ET Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Michael Wood - LifeSci Advisors Chaim Lebovits - President and Chief Executive Officer Stacy Lindborg - Co-Chief Execu...

2023-08-14 07:44:30 ET BrainStorm Cell Therapeutics press release ( NASDAQ: BCLI ): Q2 GAAP EPS of -$0.27 misses by $0.13 . Cash, cash equivalents, and short-term bank deposits were approximately $.75 million as of June 30, 2023, compared to $3.0 million as of December...

BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire FDA advisory committee (ADCOM) meeting to discuss NurOwn® for Amyotrophic Lateral Sclerosis (ALS) scheduled for September 27, 2023 BrainStorm's Bi...

BrainStorm to Announce Second Quarter 2023 Financial Results and Provide a Corporate Update PR Newswire NEW YORK , Aug. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative disea...

Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering PR Newswire NEW YORK , July 17, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics fo...

BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer PR Newswire Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases ...

2023-07-07 10:11:07 ET BrainStorm Cell Therapeutics ( NASDAQ: BCLI ) has presented new biomarker data from the Phase 3 trial of its late-stage investigational ALS treatment, NurOwn at the 2023 ALS and Related Motor Neuron Diseases Gordon Research Conference . These dat...

BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration PR Newswire New data presented this week at Gordon Research Conference Analysis reinforces NfL levels as predictive of ALS clinical outcomes ...

2023-06-20 12:59:08 ET Gainers: Evelo Biosciences ( EVLO ) +56% . DICE Therapeutics ( DICE ) +37% . Virgin Galactic Holdings ( SPCE ) +23% . MGO Global ( MGOL ) +22% . Alvarium Tiedemann Holdings ( ALTIW ) +21% . Iris Energy ...

BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair PR Newswire NEW YORK , June 20, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegen...